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Atherosclerosis is a chronic inflammatory disease of the arteries and a common cause of 
death worldwide. The disease is initiated by endothelial dysfunction that allows the 
transport of leukocytes and low-density lipoprotein (LDL) into the vessel wall where 
they form plaques. They impair the normal function of an artery. The melanocortin 
system is an endogenous modulatory system consisting of α-, β- and γ-melanocyte-
stimulating hormones (α-, β- and γ-MSH), and corticotropin (ACTH); five melanocortin 
receptors, named MC1R-MC5R; and their antagonists, agouti and agouti-related 
peptide. Short-term melanocortin treatment alleviates vascular inflammation and 
dysfunction in atherosclerosis but, for now, no study has evaluated the long-term effects 
of the melanocortin system activation on atherosclerosis progression. 
 
The aim of this study was to evaluate the effects of the transgenic melanocortin system 
activation in a mouse model of atherosclerosis. It was hypothesised that trangenic 
overexpression of the melanocortin peptides limits the progression of atherosclerosis. 
Low-density lipoprotein receptor-deficient (Ldlr-/-) mice overexpressing α- and γ3-MSH 
and their wildtype Ldlr-/- controls were fed either a regular CRM diet or high-fat and –
sugar Western-style diet for 16 weeks. During this time, their body weight and food 
consumption were monitored weekly. After the diet intervention, the aortae were 
collected for ex vivo wire-myograph analysis of the functional and mechanical 
properties of the aorta. In addition, the plaques in the aortic root and arch were 
characterised by histological and immunohistochemical stainings, and the expressions 
of inflammatory mediators were studied by reverse-transcription polymerase chain 
reaction (RT-qPCR). 
 
We found that on Western diet the melanocortin overexpression limited the plaque 
formation in the aortic arch and the expression of inflammatory cytokines (Ccl2, Ccl5 
and Il6) that contribute to the pathogenesis of atherosclerosis. In addition, the 
melanocortin overexpression alleviated the α1-adrenoceptor-mediated vasoconstriction 
and enhanced the endothelium-dependent dilation. Thus, the transgenic melanocortin 
overexpression improved the function of the aorta.  These results show for the first time 
that the transgenic activation of the melanocortin system limits the progression of 
atherosclerosis by alleviating inflammation, plaque formation and arterial dysfunction.  
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Acute complications in cardiovascular diseases (CVDs) cause more than 30% of all 
deaths, making them the number one killer worldwide (World Health Organization 
2015, Mozaffarian, Benjamin et al. 2015). In Finland in 2010, the age-standardised 
death rate of cardiovascular diseases was more than 300 per 100 000 citizens, which 
means that every fifth citizen died of coronary artery disease (Statistics Finland 2011). 
The most acute complications of CVDs originate from atherosclerosis, the formation of 
lipid-rich plaques in the vessel wall (World Health Organization 2015). Atherosclerosis 
is an inflammatory disease of the middle- and large-sized arteries and on the basis of 
current understanding it is initiated by endothelial dysfunction (Moore, Tabas 2011). 
Several factors have been suggested to cause endothelial damage, among others, 
elevated cholesterol and triglyceride concentrations in the blood (American Heart 
Association 2014). Moreover, a major risk factor for atherosclerosis is metabolic 
syndrome, which includes the sum of obesity, high blood pressure, low HDL 
cholesterol, high triglyseride levels and impared glucose homeostasis.   
 
A growing body of evidence recognises the beneficial effects of a peptide system called 
the melanocortin system (Catania, Gatti et al. 2004, Patel, Leoni et al. 2010). This 
system consists of the melanocortin peptides, α-, β- and γ-melanocyte-stimulating 
hormones (α-, β- and γ-MSH), and corticotropin (ACTH); five melanocortin receptors, 
named MC1R-MC5R (Mountjoy, Robbins et al. 1992); and their antagonists, agouti and 
agouti-related peptide (AgRP) (Gantz, Fong 2003, Cortes, Navarro et al. 2014).  
 
A wealth of evidence has recognised the benefits of the melanocortin system activation 
on cardiovascular and inflammation regulation both in vitro and in vivo (Brzoska, Luger 
et al. 2008, Catania, Lonati et al. 2010, Leoni, Patel et al. 2008, Leoni, Voisin et al. 
2010, Patel, Montero-Melendez et al. 2011, Rinne, Nordlund et al. 2013, Rinne, Silvola 
et al. 2014, Schaible, Steinstrasser et al. 2013). Recent studies have showed that α-MSH 
and its analogue, melanotan II (MT-II), evoke anti-inflammatory and vasoactive effects 
both in endothelial cells and in a mouse model of atherosclerosis (Rinne, Silvola et al. 
2014, Yang, Zhang et al. 2015). On the other hand, deficient MC1R function disturbs 
the vascular endothelial function and increases arterial stiffness both in mice and 
humans (Rinne, Ahola-Olli et al. 2015). The vasoprotective effects arise from the 
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augmentation of nitric oxide (NO) availability (Davignon, Ganz 2004, Rinne, Nordlund 
et al. 2013). The alleviation of inflammation stems, on one hand, from the inhibition of 
nuclear factor κB related gene products (Manna, Aggarwal 1998, Yang, Zhang et al. 
2015), such as pro-inflammatory cytokines, their receptors and adhesion molecules 
(May, Ghosh 1998) and, on the other hand, from the activation of anti-inflammatory 
processes (Holloway, Durrenberger et al. 2015). Apart from MC1R, MC3R is also 
instrumental in mediating the anti-inflammatory and vasoprotective effects of 
melanocortins. Pharmacological treatment with an MC3R analogue attenuates cell 
adhesion, emigration and chemokine generation, while deficiency in Mc3r manifests in 
increased extravasation and upregulation of inflammatory markers (Leoni, Patel et al. 
2008). 
 
Although the beneficial effects of the melanocortin system on immune and 
cardiovascular regulation have been clearly characterised (Catania, Gatti et al. 2004, 
Catania 2007, Catania, Lonati et al. 2010, Samuelsson 2014, Ahmed, Kaneva et al. 
2014), the therapeutic potential of long-term melanocortinergic activation remains to be 
determined. To study the long-term melanocortin system activation in atherosclerosis, 
an atherosclerotic low-density lipoprotein receptor-deficient (Ldlr-/-) mouse model that 
overexpresses α- and γ3-MSH was created and the progression of atherosclerosis in this 
transgenic disease model was evaluated. In this study, the trangenic α- and γ3-MSH 
overexpression (OE) limited the progression of vascular dysfunction, inflammation and 
plaque formation. This study shows for the first time that transgenic α- and γ3-MSH-OE 
alleviates the progression of murine atherosclerosis. 
 
2 REVIEW OF THE LITERATURE 
 




Melanocortins, α-, β- and γ-MSH, and ACTH, are biologically active, endogenous 
peptides that are cleaved from the common precursor molecule pro-opiomelanocortin 
(POMC) (Smith, Funder 1988). γ-MSH comes in three species of which γ1-MSH and γ2-
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MSH have nearly identical amino acid sequences, while γ3-MSH is a larger peptide than 
γ1- and γ2-MSH. POMC is cleaved to active melanocortins by calcium-dependent 
subtilisin-like endoproteases, called prohormone convertases PC1/3 and PC2 (Fig. 1 and 
2). The POMC gene is conserved among all mammalian species and it consists of two 
introns and three exons (Autelitano, Lundblad et al. 1989). POMC is mainly expressed 
in the pituitary, but also in the arcuate nucleus of the hypothalamus (ARC), in the 
medulla and in many peripheral tissues, such as skin, kidney and liver (Wardlaw 2011, 
Autelitano, Lundblad et al. 1989). POMC is regulated by several factors, including 
corticotropin-releasing hormone (CRH), serotonin, adrenalin, oxytocin, angiotensin II 
and bradykinin, which stimulate POMC transcription, and γ-aminobutyric acid and 
glucocorticoids, which inhibit POMC (Smith, Funder 1988, Autelitano, Lundblad et al. 
1989).     
 
 
Fig. 1. The melanocortin system consists of endogenous melanocortins and 
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Fig.  2. POMC is posttranscriptionally processed to active melanocortins. 
Melanocortins peptides, α-, β- and γ-MSH, and ACTH, are enzymatically cleaved from 
a common prohormone precursor protein POMC. N-POC, N-terminal peptide; JP, 
joining peptide; N-AT, N-acetyltransferase; PAM, peptidylglycine α-amidating mono-
oxygenase; CPE, carboxypeptidase; CLIP, corticotropin-like intermediate lobe peptide.  
 
2.1.2 Melanocortin receptors 
 
Melanocortins mediate their effects via five melanocortin receptors (MC1R-MC5R). 
MCRs are the smallest stimulatory G-protein coupled receptors (GPCR) identified to 
date with a short extracellular N-terminus and intracellular C-terminus. The 
melanocortin system is an exceptional peptide system because it contains both 
endogeneous agonists as well as antagonists although this chapter mainly focuses on 
MCRs and their agonists.  
 
MC1R is a classic melanocortin receptor that has a high affinity for α-MSH and ACTH 
(Mountjoy, Robbins et al. 1992, Chhajlani, Wikberg 1992). MC1R is expressed in 
dermal fibroblasts, keratinocytes and melanocytes, but also in the immune and 
endothelial cells. In the skin, the ligand-receptor interaction stimulates the synthesis of 
eumelanin and induces pigmentation when the skin is exposed to ultraviolet (UV) light 
(Abdel-Malek, Swope et al. 1995, Hunt, Todd et al. 1994, Robbins, Nadeau et al. 1993). 
This biological response is beneficial because it protects the skin from UV light-induced 
genomic damage (Rees 2003). UV light provokes the production of α-MSH in the skin 
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where α-MSH acts in a paracrine manner to alleviate inflammation. Pigmentation is 
altered by MC1R mutations and polymorphisms (Robbins, Nadeau et al. 1993, Koppula, 
Robbins et al. 1997). Along with skin, MC1R is present in the cells of the immune 
system (Star, Rajora et al. 1995, Bhardwaj, Becher et al. 1997, Neumann Andersen, 
Nagaeva et al. 2001, Catania, Rajora et al. 1996, Becher, Mahnke et al. 1999), playing 
an important role in immunomodulation. In addition, weak MC1R signalling has been 
linked to defects in arterial vasodilatation and distensibility (Rinne, Ahola-Olli et al. 
2015).  
 
MC2R binds only ACTH, which is why it is also called the ACTH receptor. MC2R is 
expressed in the adrenal cortex, where it stimulates the synthesis of corticosteroids, such 
as cortisol in humans and corticosterone in rodents (Tsigos, Arai et al. 1993) that 
regulate glucose metabolism and immune responses (Xia, Wikberg 1996, Lefkowitz, 
Roth et al. 1970, Mountjoy, Robbins et al. 1992). MC2R is also expressed in adipocytes 
in mice, where it mediates lipolysis (Boston, Cone 1996). 
 
MC3R (Gantz, Konda et al. 1993) is mainly expressed in the hypothalamus in the 
central nervous system (CNS) (Roselli-Rehfuss, Mountjoy et al. 1993), but also in a 
variety of other tissues, such as, in the heart, gut, placenta (Gantz, Konda et al. 1993), 
macrophages (Lam, Perretti et al. 2006) and B cells (Cooper, Robinson et al. 2005). 
MCR3 is the only MCR subtype that responds highly to γ-MSH (Roselli-Rehfuss, 
Mountjoy et al. 1993). However, MC3R is also activated by other melanocortin 
peptides. MC3R contributes to immunomodulation (Getting, Gibbs et al. 1999, Getting, 
Allcock et al. 2001), energy homeostasis and feeding behaviour (Marks, Hruby et al. 
2006). 
 
Moreover, MC4R is present in the CNS (Mountjoy, Mortrud et al. 1994, Gantz, Miwa et 
al. 1993). However, compared to MC3R, MC4R is more wide-spread within the CNS 
(Mountjoy, Mortrud et al. 1994). MC4R contributes to the central regulation of 
cardiovascular dynamics (Dunbar, Lu 2000, Matsumura, Tsuchihashi et al. 2002), 
energy homeostasis and feeding behaviour (Huszar, Lynch et al. 1997). MC4R is 
activated by α- and β-MSH and ACTH, but also by γ-MSH although with lower 
affinity. 
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MC5R is expressed in a variety of peripheral tissues, such as thymus, spleen and 
exocrine glands (Gantz, Shimoto et al. 1994, Labbe, Desarnaud et al. 1994). This 
receptor subtype contributes to the lipid mobilisation and synthesis and secretion of 
exocrine products (Boston, Cone 1996, Chhajlani, Muceniece et al. 1993, Chen, Kelly et 
al. 1997). MC5R may also have a role in inflammation control because it is expressed in 
B cells (Buggy 1998), T cells (Taylor, Namba 2001) and mast cells (Artuc, Grutzkau et 
al. 1999). MC5R responds to α‑MSH that has higher affinity than β‑MSH and ACTH. γ-
MSH activates MC5R, too, but has weaker affinity than the above-mentioned agonists. 
 
The distribution, function and endogeneous agonists and antagonists of five MCR 
subtypes are presented in Table 1. 
 
Table 1. The properties of the melanocortin receptor subtypes (modified from 
(Caruso, Lagerstrom et al. 2014)). GI-tract, gastrointestinal tract. 






Skin, immune cells, 

























































2.1.3 Synthetic melanocortin peptides 
 
The synthetisation of melanocortin-like peptides has enabled the recognition of the 
amino acids that mediate the receptor-ligand interaction in MSHs (Hruby, Sawyer et al. 
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1980, Sawyer, Hruby et al. 1982). This core heptapeptide, His-Phe-Arg-Trp, is crucial 
for mediating the cellular responses of MSHs because MCRs recognise and bind to this 
structure (Haskell-Luevano, Sawyer et al. 1996, Sawyer, Hruby et al. 1982) (Fig. 3).  
 
 
Fig. 3. The amino acid sequences of endogenous α-, β- and γ-melanocyte 
stimulating hormones (α-, β- and γ-MSH, respectively). All MSHs share a core 
amino acid sequence that is represented in blue. This core sequence is crucial for the 
ligand-receptor interaction (modified from (Humphreys, Lin 1988)). 
 
Afamelanotide, also known as melanotan I or [Nle4-D-Phe7]-α-MSH, is one of the first 
synthesized α-MSH analogues (Sawyer, Sanfilippo et al. 1980). Compared with 
endogenous α-MSH, afamelanotide has a prolonged bioactivity because it is more 
resistant to enzymatic degradation (Sawyer, Sanfilippo et al. 1980, Hadley, Anderson et 
al. 1981). Similar to α-MSH, afamelanotide protects the skin from UV radiation. Due to 
its photoprotective action, afamelanotide has recently been approved for the treatment 
of erythropoietic protoporphyria (Minder 2010).  
 
Another α-MSH analogue, MT-II, is as potent as its parent compound afamelanotide in 
inducing skin pigmentation. Unlike afamelanotide, MT-II is able to cross the blood-
brain barrier (BBB) and move to the CNS, where it acts as an anorexigenic agent, i.e. it 
reduces food intake. Due to the tanning and anorexigenic effects, MT-II is also called as 
a “Barbie drug” and used unlicensed for cosmetic reasons. As a side effect, MT-II 
causes unintentional erections in men. This observation led to the development of PT-
141 or bremelanotide that has been approved for the treatment of female sexual 
dysfunction (Diamond, Earle et al. 2006). Because of their central role in the regulation 
of energy homeostasis and food intake, several melanocortin agonists, both non-
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selective MC3R/MC4R and selective MC4R agonists, are currently being investigated 
for the treatment of obesity (Fani, Bak et al. 2014).  
 
The amino acid sequences of α-MSH and its synthetic analogues MT-I and MT-II are 
presented in Fig. 4.  
 
 
Fig. 4. The amino acid sequences of endogenous α-MSH and its synthetic analogues 
MT-I and MTII. The core sequence of MSHs is presented in blue (Hadley, Dorr 2006). 
 
2.2 Physiological functions of the melanocortin system 
 
Over the past years, it has been demonstrated that melanocortins play an important role 
in maintaining health and homeostasis (Cone 2006) (Fig. 5). The cells are constantly 
under intrinsic or external stressors, such as pathogens or UV radiation, which disturb 
the cellular homeostasis. The stress response is mainly mediated via the hypothalamus-
pituitary-adrenal (HPA) axis. When it is activated, CRH is produced in the 
hypothalamus, from where it is transported to the portal circulation (Popa, Fielding 
1933, Harris 1948) and to the anterior pituitary. There CRH promotes the synthesis of 
POMC (Affolter, Reisine 1985). POMC products, ACTH and MSHs, are secreted to the 
systemic circulation, where they are delivered to their target tissues. In the periphery, 
melanocortins bind to MCRs and induce the production of mediators, for example, 
glucocorticoids from the adrenal gland. Then, the mediators alleviate the stress response 
and also convey negative feedback to the pituitary and hypothalamus. (Slominski, 
Wortsman et al. 2000) 
 
At a cell level, binding of a melanocortin ligand to its receptor activates adenylyl 
cyclase (AC) (Sawyer, Hruby et al. 1982, Tatro, Entwistle et al. 1990), which converts 
ATP to cyclic adenosine monophosphate (cAMP). cAMP is a secondary messenger that 
activates protein kinase A (PKA) (Mountjoy, Robbins et al. 1992). PKA regulates the 
phosphorylation of cAMP response element-binding protein (CREB) that interacts with 
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cAMP response element (CRE) at the promoter area and activates transcription of an 
anti-inflammatory gene, for example, CRH (Sarkar, Legradi et al. 2002). 
 
    
Fig. 5. Melanocortin system regulates several physiological functions in order to 
maintain homeostasis. 
 
Some of the key functions of the melanocortin system potentially related to 
atherosclerosis are discussed in this chapter.  
 
2.2.1 Energy homeostasis 
 
Today, obesity is a worldwide health issue and a risk factor for cardiovascular and other 
diseases (Nguyen, Lau 2012). Obesity increases the risk for diabetes and the 
hyperglycemia related to diabetes increases the risk for atherosclerosis. The central 
melanocortin system is an important regulator of the energy homeostasis (Nuzzaci, 
Laderriere et al. 2015). The regulatory centre of this system lies in the ARC. This 
nucleus contains two types of neuron populations: the POMC and the 
AgRP/neuropeptide Y (NPY) neurons (Cowley, Pronchuk et al. 1999) that mediate 
opposing effects. AgRP/NPY neurons express orexigenic molecules such as NPY and 
AgRP, thus increasing appetite (Clark, Kalra et al. 1984, Stanley, Leibowitz 1984, Fani, 
Bak et al. 2014), whereas POMC neurons express anorexigenic signals, such as POMC 
and cocaine- and amphetamine-regulated transcript, hence mediating the satiety 
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response (Cowley, Pronchuk et al. 1999, Fani, Bak et al. 2014). Together, these neurons 
of the central melanocortin system regulate the food intake and metabolic status. 
 
A number of studies demonstrate the relevance of the melanocortin precursor POMC in 
the regulation of energy metabolism (Nuzzaci, Laderriere et al. 2015). Deficiencies in 
POMC or the deletion of Pomc results in obesity in humans and in mice, respectively 
(Yaswen, Diehl et al. 1999, Greenman, Kuperman et al. 2013). On the other hand, OE 
of POMC peptides protects from obesity (Savontaus, Breen et al. 2004). POMC neuron 
activity and POMC expression are modulated by several peripheral metabolic signals 
(Jeong, Kim et al. 2014). These signals include blood glucose, pancreas-derived insulin 
and adipose tissue-originated leptin. In response to these signals, POMC is upregulated 
and cleaved to melanocortin peptides. As a result, POMC product α-MSH decreases 
appetite via binding to MC4R in the paraventricular hypothalamus (Schwartz, Seeley et 
al. 1997, Fani, Bak et al. 2014). AgRP/NPY neurons, on the other hand, are negatively 
regulated by insulin or leptin. 
 
An essential mediator of the central melanocortin system is MC4R. The administration 
of an MC4R antagonist or the deletion of Mc4r restrains the connection between the 
POMC neurons and the anorexic neurons, which causes obesity (Fan, Boston et al. 
1997, Huszar, Lynch et al. 1997). On the other hand, the activation of MC4R in 
anorexic neurons reduces appetite (Fan, Boston et al. 1997). These mouse data are 
consistent with the human data, because in humans, rare loss-of-function mutations in 
MC4R are often associated with obesity (Farooqi 2008, Rene, Le Gouill et al. 2010). 
MC3R plays also a role in the control of energy balance, but the correlation between 
MC3R variants and obesity is less evident than that of MC4R (Li, Joo et al. 2000). 
 
In addition to several satiety-related molecules, energy balance is modulated by 
inflammatory mediators. In rats, endotoxin LPS promotes POMC expression in the CNS 
and reduces food intake. The authors speculate that the cytokine-release induced by LPS 
would increase plasma leptin level, which in turn, activates POMC neurons, and further, 
α-MSH production. (Sergeyev, Broberger et al. 2001)  Moreover, high-fat diet increases 
the expression of pro-inflammatory cytokines and nuclear factor κB (NF-κB) pathway 
genes in the hypothalamus. This response is independent of the weight gain because 1 to 
3 days on the diet already activates the hypothalamic inflammation. Furthermore, one 
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week on the high-fat diet reduces the number of POMC neurons in mice and in rats. The 
rodent data are consistent with human magnetic resonance imaging findings, which 
demonstrate that obesity is associated with mediobasal hypothalamic injury. (Thaler, Yi 
et al. 2012)  
 
2.2.2 Cardiovascular system 
 
The melanocortin system regulates the cardiovascular system, including blood pressure 
and endothelial function. The effects of melanocortins on blood pressure regulation are 
complex because these peptides may have either hypotensive or hypertensive effects 
depending on the dose and the site of action (Callahan, Kirby et al. 1984, Lymangrover, 
Buckalew et al. 1985). 
 
The primary melanocortin regulating blood pressure is γ-MSH. Deficiency in γ-MSH, 
caused by genetic deletion of PCs that process POMC to γ-MSH, leads to salt-sensitive 
hypertension (Mayan, Ling et al. 1996). On the other hand, an acute administration of γ-
MSH elevates the blood pressure and heart rate temporarily (Callahan, Kirby et al. 
1988, Ni, Butler et al. 2006). However, the hypertensive effects of γ-MSH are not 
mediated via MC3R but via FMRFamide gated sodium channels (Versteeg, Van Bergen 
et al. 1998, Ni, Butler et al. 2006). Furthermore, α- and γ3-MSH-OE elevates the blood 
pressure, but not the heart rate (Rinne, Harjunpää et al. 2008). These effects are likely 
mediated via central sympathetic stimulation (Callahan, Kirby et al. 1988, Ni, Butler et 
al. 2006). 
 
While γ-MSH mediates its effect via FMRFamide gated sodium channels, α-MSH 
exerts its centrally mediated cardiovascular effects via MC4R activation (Ni, Butler et 
al. 2006). Intracerebroventricularly administered α-MSH increases the blood pressure 
and heart rate via sympathetic activation (Ni, Butler et al. 2006), whereas α-MSH 
administration into nucleus tractus solitarii in medulla decreases blood pressure and 
heart rate (Tai, Weng et al. 2007). α-MSH analogue [Nle4-D-Phe7]-α-MSH shows 
distinct effects in mice and in rats when administered intravenously. In rats, there are no 
cardiovascular effects, while mouse studies show an elevation in both heart rate and 
blood pressure (Van Bergen, Kleijne et al. 1997, Rinne, Tikka et al. 2012). 
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In addition to its central actions, α-MSH regulates the cardiovascular system in the 
periphery. In the vascular endothelium, α-MSH enhances NO synthesis, thus inducing 
vasorelaxation and protecting the endothelium (Rinne, Nordlund et al. 2013). These 
beneficial effects are disrupted in Mc1re/e mice that lack functional Mc1r (Rinne, Ahola-
Olli et al. 2015). Mc1r deficiency hardens the aorta, impairs the endothelium-dependent 
vasodilatation and predisposes to vascular inflammation (Rinne, Ahola-Olli et al. 2015). 
Thus, the beneficial effects of α-MSH on vascular endothelium seem to be mediated via 
MC1R. 
 
2.2.3 Immune system 
 
Already in 1950, Hench observed that ACTH alleviates the symptoms of rheumatoid 
arthritis (Hench 1950). Since, the therapeutic potential of the melanocortin treatment 
has expanded to include not only gouty arthritis but also other inflammatory disorders. 
Today, the melanocortin treatment has been documented to be beneficial in several 
preclinical models of inflammatory diseases (Catania, Lonati et al. 2010). Moreover, in 
clinic, ACTH is already being used for the treatment of multiple sclerosis relapses. 
 
The melanocortin system has anti-inflammatory, immunomodulatory and anti-microbial 
properties in the immune cells (Catania 2008) and almost all types of leukocytes express 
MCRs (Catania 2007) (Fig. 6). This chapter discusses the mechanisms by which 
melanocortins mediate their immunomodulatory actions and the role of melanocortin 
system in specific cells of the immune system that relate to atherosclerosis. 
 
 
Fig. 6. The melanocortin receptor expression in the immune cells. Melanocortin 
receptors are widely expressed in the immune system. Clipart pictures of the immune 
cells retrieved from www.clker.com.  
 
2.2.3.1 Anti-inflammatory signalling pathways of the melanocortin system 
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Inflammatory response is a defence mechanism that restricts the tissue damage and 
initiates the healing process. Inflammation responses can be classified as acute and 
chronic inflammatory responses. In acute inflammation, neutrophils dominate the 
inflammatory site and secrete proteins from their granules into the surrounding tissue. 
The later stage, when the neutrophils have been replaced by monocytes, lymphocytes 
and plasma cells, is called the chronic inflammatory response and is mediated by 
adaptive immunity. Eventually, the inflammatory response leads to resolution and 
healing. Sometimes the inflammatory response can be too extensive or chronic. 
Therefore, anti-inflammatory mechanisms are needed in order to resolve the 
inflammation. The melanocortin system alleviates inflammation particularly at its early 
stage by inhibiting the production of cytokines and growth factors, cytokine receptors, 
leukocyte adhesion molecules and stress proteins.  
 
Melanocortins mediate their anti-inflammatory effects via three main pathways. 
1. Melanocortins can modulate the action of peripheral immune cells via 
descending anti-inflammatory pathways and via HPA axis. 
2. Melanocortin can inhibit the immune response by decreasing the secretion of 
inflammatory mediators by the immune cells. 
3. Melanocortins can inhibit the inflammation locally in the CNS. 
Next, these pathways are discussed in more detail. 
 
In addition to the HPA axis that was discussed earlier, melanocortins mediate their anti-
inflammatory effects via descending pathways (Macaluso, McCoy et al. 1994). When 
melanocortins bind to the central MC3R or MC4R, the ligand-receptor interaction 
activates the cholinergic and brain-spinal cord adrenergic circuits. These pathways 
mediate the anti-inflammatory effects to the peripheral immune cells via nicotinic and 
β2 adrenergic receptors, respectively (Matsumura, Tsuchihashi et al. 2002). Animal 
studies using spinal cord transections highlight the relevance of an intact spinal cord.  In 
transectioned animals, the melanocortin-induced anti-inflammatory effects remain lower 
compared to intact animals. The same effect is observed when peripheral β2 receptor 
antagonist, for example, propranolol is administrated (Macaluso, McCoy et al. 1994). 
These evidence show that the immunomodulation evoked by the melanocortin system is 
a sum of peripheral and central actions; thus, immunodulation is often more extensive in 
a living organism than in vitro. 




Melanocortins can also act locally in the CNS by binding to the melanocortin receptors 
in the glia. Within the CNS, melanocortins alleviate the central inflammation and 
protect cells against neuronal damage. Such protection could be beneficial, for example, 
in the case of traumatic brain injury (Schaible, Steinstrasser et al. 2013). 
 
At the transcriptional level, melanocortins mediate their effects via inhibition of the 
transcription factor NF-κB that is responsible for the activation of several inflammatory 
genes, including proinflammatory cytokines and chemokines, growth factors and 
inducible nitric oxide synthase (iNOS) (Fig. 7) (Manna, Aggarwal 1998). Normally, 
NF-κB is located in the cytoplasm, where it is bound to the inhibitory proteins of IκB 
family. However, when a cell is exposed to an inflammatory stimulus, such as, 
pathogen, chemokine or endotoxin from bacteria, IκB is phosphorylated and degraded. 
Then, free NF-κB is able to translocate to the nucleus, where it binds to the promoter 
area of an inflammatory gene activating its transcription. This cascade mediates an 
inflammatory response. But when melanocortins bind to MCRs, they inhibit the 
translocation of NF-κB to the nucleus and therefore, prevent the initiation of an 
inflammatory response. Moreover, glucocorticoids, induced by ACTH, activate the 
transcription of IκB that inhibits the translocation of NF-κB (Scheinman, Cogswell et al. 
1995). Hence, melanocortins alleviate inflammation at an early state of an immune 
response. For this reason, the inhibition of NF-κB by melanocortin treatment appears as 
an ideal drug development target for a variety of inflammatory disorders (Catania, 
Lonati et al. 2010).  
 




Fig. 7. Genes under regulation of NF-κB. NF-κB upregulates several inflammatory 
genes when a cell is exposed to an inflammatory stimulus, for example, bacterial 
lipopolysaccharide (LPS). Melanocortins alleviate inflammation by inhibiting NF-κB, 




Neutrophils compose 40-75% of blood leukocytes in humans, making them the most 
common circulating leukocyte subtype. The migration of neutrophils is the first and 
most important step in the acute immune response. During the acute inflammation, 
neutrophils phagocytose and destroy the pathogens and wounded cells. 
 
During the acute inflammation, neutrophils attach to the endothelial adhesion molecules 
and extravasate from the blood to the tissue. The extravasation is mediated by IL8 that 
binds to CXCR receptors on neutrophils. This interaction unbinds NF-κB from its 
inhibitory proteins and triggers the expression of inflammatory mediators as described 
earlier. Neutrophils express MC1R on their cell surface. MC1R/α-MSH interaction 
downregulates CXCR; and thus, α-MSH restrains the activation of acute neutrophil-
driven immune response. (Manna, Sarkar et al. 2006) 
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2.2.3.3 Dendritic cells 
 
Dendritic cells are the bridge between the innate and adaptive immunity. They 
recognise, phagocytose and destroy the pathogens. The destroyed pathogen fragments, 
also called as epitopes, are then presented to naïve CD (cluster of differentiation) 4+ T 
cells in the lymph nodes. The antigen presentation is mediated via major 
histocompatibility complex (MHC) II molecule and T cell receptor (TCR) interaction. 
The antigen presentation enables the differentiation of CD4+ T cells into Th1, Th2, Th17 
or Treg cells, depending on the surrounding cytokines. 
 
In addition to MHC II and TCR, costimulatory molecules are needed for the antigen 
presentation and T cell survival. These molecules include CD86 and CD40 that are 
expressed on the surface of antigen presenting cells, including dendritic cells. Dendritic 
cells express MCR 1, 2, 4 and 5 subtypes. Binding of α-MSH to MC1R induces 
tolerogenic dendritic cells and expansion of regulatory T cells (Auriemma, Brzoska et 
al. 2012). α-MSH-mediated tolerance is characterised by decreased expression of 
costimulatory molecules (Auriemma, Brzoska et al. 2012). In addition, α-MSH 
downregulates the proliferation of Th17 effector cells (Auriemma, Brzoska et al. 2012). 
Together, α-MSH inhibits the progression of cell-mediated inflammation. 
 
2.2.3.4 Monocytes and macrophages 
 
Monocytes are circulating leukocytes. As they move to the inflamed tissue, they 
differentiate into macrophages. Their role is to destroy cells that are infected by 
microbes and present the epitopes to other immune cells. Activated macrophages also 
recruit other immune cells to the site of inflammation by secreting chemokines, i.e. 
chemotactic cytokines. 
 
Melanocortins modulate chemotaxis by inhibiting the secretion of pro-inflammatory 
cytokines from macrophages (Patel, Montero-Melendez et al. 2011). For example, the 
selective MC3R agonist [D-Trp8]-γ-MSH alleviates the secretion of chemokines 
CXCL1 and chemokine (C-C motif) ligand 2 (CCL2). This effect is absent in Mc3r 
knockout mice (Leoni, Patel et al. 2008). Similarly, MC3R deficiency increases the 
expression of interleukin 1β (Il1β), interleukin 6 (Il6), inos, Ccr4, Cxcr3 and Ccl2 in the 
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mouse joint samples compared with wildtype (WT) (Patel, Leoni et al. 2010). This 
evidence shows that MC3R contributes to the anti-inflammatory actions of the 
melanocortin system. 
 
In addition to MC3R, MC1R mediates the anti-inflammatory actions of melanocortins 
in macrophages (Catania, Gatti et al. 2004). On the contrary to MC3R, MC1R 
expression is markedly upregulated upon endotoxin stimulation leading to the 
suppression of NF-κB-related gene products. These effects are absent in MC1R siRNA 
knockdown macrophages. (Li, Taylor 2008)  
 
Melanocortins also influence the polarisation of macrophages. Rinne et al. showed that 
long-term MT-II treatment could induce the polarisation of macrophages into anti-
inflammatory M2 type and inhibit the expression of proinflammatory molecules (Rinne, 




In humans, 20-30% of the blood leukocytes are lymphocytes. They include B, T and 
natural killer (NK) cells. Activated B cells, plasma cells, secrete antibodies against the 
pathogen mediating the humoral immunity. T cells, on the contrary, act locally in the 
lymph tissue or at the site of inflammation playing a role in the cell-mediated immunity. 
B and T cells belong to acquired or adaptive immune system, whereas NK cells are a 
part of the innate immunity. NK cells destroy cells that are infected by viruses and some 
cancer cells, i.e. those that are unable to express MHC I on their cell surface. 
 
The melanocortin system plays a role in the differentiation of B cells. ACTH and its 
fragment ACTH1-24 maintain the growth of B cells and increase the antibody production 
(Alvarez-Mon, Kehrl et al. 1985). In addition, α-MSH and its analogue [Nle4-D-Phe7]-
α-MSH stimulate the growth of B cells (Buggy 1998).  
 
α-MSH also modulates the T cell response. The interaction of α-MSH and MC5R 
induces the CD25+ and CD4+ T cells to produce anti-inflammatory transforming growth 
factor β1. (Taylor, Namba 2001) 
 




2.3 The pathogenesis of atherosclerosis 
 
Although atherosclerosis is characterised and known by lipid-rich subendothelial 
plaques, it is primarily an inflammatory disorder. Several factors, including elevated 
cholesterol and triglyceride concentrations, initiate the maladaptive immune response in 
the arteries, which eventually leads to the endothelial dysfunction, recruitment of 
immune cells, entrapment of lipids and formation of atherosclerotic plaques. The 
preceding factors are discussed in this chapter.  
 
2.3.1 Endothelial dysfunction 
 
The arteries are composed of different types of layers: the outermost layer, tunica 
adventitia, is mainly composed of collagen; tunica media, is composed of smooth 
muscle cells and fibrous tissue; and the innermost layer, tunica intima, supports the 
cellular monolayer, the endothelium. These three layers are separated by elastic lamina. 
The disturbance of endothelium is a key step in the development of atherosclerosis 
(Davignon, Ganz 2004). 
 
The innermost surface of the vasculature, endothelium, is the barrier between the blood 
material and vascular wall. The endothelium is structured by calveolae vesicles, which 
enable the transendothelial transport of various substances to the vessel wall. Thus, the 
endothelium controls the delivery of various substances from the blood into the tissue 
and vice versa (Chistiakov, Orekhov et al. 2015). The transendothelial transport is 
crucial in both health and disease, because it is needed for angiogenesis, immune 
response, vascular remodelling and tissue repair (Chistiakov, Orekhov et al. 2015). In 
healthy vasculature, the permeability of the endothelium is limited. However, upon 
stressful conditions, such as ischemia or oxidative stress, the endothelial barrier function 
is impaired. This leads to increased endothelial permeability that is the initiating event 
of a vascular disease.  
 
The damaged endothelium produces vascular cell-adhesion molecule 1 (VCAM1), 
which initiates the immune response in the intima (Cybulsky, Gimbrone 1991, 
Cybulsky, Iiyama et al. 2001). VCAM1 interacts with very late antigen 4 (VLA4) on the 
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surface of circulating T cells and monocytes, promoting their arrest in the endothelium 
(Hansson, Libby 2006). Infiltrated immune cells secrete pro-inflammatory chemokines, 
such as CCL2, that further recruit immune cells into the vascular wall. CCL2 and 
chemokine (C-C motif) ligand 5 (CCL5) play a crucial role in the development of 
atherosclerosis because the blocking of their action by knockout models or antagonists 
alleviates atherogenesis in mice (Boring, Gosling et al. 1998, Gu, Okada et al. 1998). 
Moreover, another adhesion molecule, ICAM1, is upregulated in the intimal layer of the 
atherosclerotic plaques, but it has a minor role in the initiation of the disease (Cybulsky, 
Iiyama et al. 2001). The infiltration of immune cells happens at the first stage of 
atherosclerosis development; thus these molecules play a crucial role in the disease 
pathogenesis (Hansson, Libby 2006). 
 
One of the most important functions of the endothelium is to regulate the vascular tone, 
i.e. the balance between vasoconstriction and vasodilatation. In the damaged 
endothelium, the endothelium-dependent vasorelaxation is compromised due to a low 
bioavailability of NO, which shifts the vascular tone towards vasoconstriction (Ludmer, 
Selwyn et al. 1986). This effect can be observed even before the clinical manifestation 
of the disease, suggesting that the endothelial dysfunction is an early marker for 
atherosclerosis (Ludmer, Selwyn et al. 1986).  
 
NO is produced by enzymes called nitric oxide synthases (NOS), which appear in three 
isoforms: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS) nitric oxide 
synthases (Bredt, Hwang et al. 1990). nNOS is mainly expressed in the nervous system, 
while eNOS is present in the vascular endothelium, where it induces NO production in 
response to acetylcholine (ACh) or bradykinin (Fleming, Busse 2003). Most NO is 
produced by eNOS. The vasodilative influences of NO can be prevented 
pharmacologically by a competitive NOS inhibitor Nω-Nitro-L-arginine (L-NNA). In 
addition to vasodilatation, eNOS inhibits platelet aggregation, leukocyte adhesion and 
proliferation of vascular smooth muscle cells (Forstermann, Closs et al. 1994), which 
contribute to the development of atherosclerosis. Hence, eNOS is considered as an 
antiatherogenic enzyme (Fleming, Busse 2003). Both nNOS and eNOS are constantly 
translated, while iNOS is induced by an inflammatory stimulus, such as LPS, IL1β, 
TNF-α and oxidative stress, in the vasculature and immune cells (Kleinert, Boissel et al. 
2000, Fleming, Busse 2003). iNOS expression is under the control of NF-κB (Kleinert, 
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Boissel et al. 2000); thus, iNOS can be considered as a marker for inflammation. 
Indeed, iNOS is upregulated in various inflammatory diseases and its expression level 
correlates with the disease severity (Kröncke, Fehsel et al. 1998). When induced, iNOS 
promotes the synthesis of vascular endothelial growth factor and collagen that enhance 
wound healing (Thornton, Schäffer et al. 1998). However, these processes also 
contribute to the pathogenesis of atherosclerosis.  
 
2.3.2 Lipid oxidation 
 
The main feature of atherosclerosis is subendothelial plaques, which compose of 
fibrosis, dead cells, inflammatory cells and lipids, including low-density lipoprotein 
(LDL) (Hansson, Libby 2006). LDLs are lipid carrier complexes that deliver cholesterol 
in the blood. A component of LDL, apolipoprotein B-100 (ApoB100), interacts with 
low-density lipoprotein receptor (LDLR) and mediates the intake of LDL into the cell. 
High lipid concentrations in the blood are associated with atherosclerotic lesion 
formation and defects in LDLR cause high blood cholesterol and heart attacks at young 
age (Brown, Goldstein 1986). The progression of atherosclerosis is halted when the 
LDL concentration is below 2 mmol/l and regressed when the concentration is 0.5-1.5 
mmol/l. On the grounds of this observation, Ldlr-/- mouse fed with high cholesterol diet 
is often used as a disease model for human atherosclerosis (Ylä-Herttuala, Bentzon et al. 
2011). Crossbreeding of Ldlr-/- mice with other knockout mice enables to study the 
mechanisms that affect the development of atherosclerosis (Hansson, Libby 2006). 
 
The circulating LDL is able to accumulate to the proteoglycan structures in the intima in 
the absence of luminal elastin barrier and in the presence of exposed 
collagen/proteoglycan network (Kwon, Schroeder et al. 2008). Because there is no 
lymphatic system in the intima, the removal of LDL particles is very slow. Upon 
oxidative stress, subendothelial LDL accumulation leads to the oxidation of the lipids. 
Macrophages recognise and internalise the modified LDL particles via scavenger 
receptors with high affinity, which further triggers the immune response and the 
endothelial damage in the vasculature (Weber, Noels 2011). This leads to the 
subendothelial thickening of the intima, i.e. the formation of early lesions, fatty streaks. 
The current treatment of atherosclerosis aims at lowering plasma LDL levels which 
reduces the entrapment of LDL to the intima. However, none of the current treatments 
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inhibit the LDL oxidation itself. Despite the strong evidence of the role of LDL in the 
development of atherosclerosis, the LDL modification hypothesis has also been 




The monocyte-derived macrophages are the main component of the plaques (Schaffner, 
Taylor et al. 1980). The internalisation of native LDL by macrophages is relatively 
slow, but when LDL is modified, the engulfment of LDL is more rapid (Henriksen, 
Mahoney et al. 1981). When exposed to modified LDL, endothelial cells and smooth 
muscle cells in the arteries secrete macrophage-stimulating factor (M-CSF) and 
granulocyte macrophage-stimulating factor (GM-CSF), which drive the differentiation 
of monocytes into macrophages (Smith, Trogan et al. 1995). The differentiation 
amplifies the expression of Toll-like receptors (TLRs) and the scavenger receptors (for 
example CD36 and CD68) on the cell membrane of macrophages that then internalise 
the modified LDL (Goldstein, Ho et al. 1979, Kodama, Reddy et al. 1988, Nicholson, 
Frieda et al. 1995, Ramprasad, Terpstra et al. 1996, Medzhitov, Preston-Hurlburt et al. 
1997, Edfeldt, Swedenborg et al. 2002). Excessive lipid accumulation in macrophages 
eventually leads to the formation of foam cells (Moore, Tabas 2011). 
 
The internalisation of LDL by macrophages protects the endothelial and smooth muscle 
cells from the damaging effect of oxidised lipids, but it also promotes the production of 
pro-inflammatory cytokines, such as IL1 that furthers and maintains the inflammation in 
the vasculature (Hajjar, Haberland 1997). In the late state of atherosclerosis, foam cells 
may be subjected to necrosis, hereby promoting the lipid core formation of the lesion as 
the internalised lipids are released to the extracellular space (Viola, Soehnlein 2015). 
 
Macrophages, among other types of cells, secrete matrix metalloproteases (MMPs) as 
an adaptive response to atheroma formation (Sarén, Welgus et al. 1996, Ylä-Herttuala, 
Bentzon et al. 2011). The substrates of MMPs include collagen, elastin, gelatine, matrix 
glycoproteins, and proteoglycans; thus, they degrade extracellular matrix (Newby 
2006). MMPs degrade the collagen fibres in the atheroma, which thins the fibrous cap 
and makes it more susceptible to rupture (Vacek, Rehman et al. 2015). Therefore, the 
increased MMP secretion correlates with instable lesions (Vacek, Rehman et al. 2015). 
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Indeed, plaques with a thin cap and lipid-rich necrotic core are thought to be most 
vulnerable to rupture, and therefore, prone to cause clinical events, such as myocardial 
infarction (Ylä-Herttuala, Bentzon et al. 2011). 
 
Infiltrated monocytes can develop into various classes of macrophages depending on the 
environment in the arterial wall, i.e. the exposure to growth factors (GM-CSF, G-CSF), 
cytokines (TNF-α, interferon γ, IL4, IL10 and IL13), chemokines (CXCL4) and other 
substances including oxLDL (Viola, Soehnlein 2015). The most thoroughly studied 
populations are M1 and M2 macrophages, which can be classified as pro-inflammatory 
and anti-inflammatory macrophages, respectively (Stein, Keshav et al. 1992, Edwards, 
Zhang et al. 2006). However, the distribution of macrophages into two classes is 
complex because M1 and M2 macrophages share similar features. It is also unclear 
whether macrophage polarisation is determined once or if it is a constantly adaptable 
process depending on the continuously changing environment (Mantovani, Garlanda et 
al. 2009). The presence of TNF-α and interferon γ favours M1 polarisation, whereas 
IL4, IL10 and IL13 exposure drives M2 macrophage phenotype (Viola, Soehnlein 
2015). M1 macrophages are considered to impair the production of eNOS. Furthermore, 
pro-inflammatory iNOS expression is increased in M1 type macrophages in several 
inflammatory diseases. iNOS expression is under the control of NF-κB. However, anti-
inflammatory mediators, such as IL10, suppress NF-κB, and thus, decrease the 
expression of pro-inflammatory mediators (Wang, Wu et al. 1995, Ckless, van der Vliet 
et al. 2007). In atherosclerosis, pro-inflammatory M1 macrophages dominate, sustaining 
the inflammation in the vasculature (Viola, Soehnlein 2015).  
 
Macrophages, along with dendritic cells, can also act as antigen-presenting cells (APCs) 
that attract and activate T cells. Foam cells that have internalised oxLDL can activate 
adaptive immunity by processing and presenting a fragment of oxLDL, ApoB, to CD4+ 
T cells via the interaction of TCR and MHC II. Antigen presentation activates CD4+ T 
cells to TH1 cells, which mediate the inflammation by producing cytokines, including 
IL12, IL18, interferon γ and TNF-α. It has been demonstrated that TH1 cytokines 
outnumber in atherosclerosis.  Because TH2 cells inhibit TH1 response, it has been 
proposed that atherosclerosis could be alleviated by inhibiting TH1 response. (Hansson, 
Libby 2006) 
 
                 28 
 
 
The pathogenesis of atherosclerosis is illustrated in Fig. 8. 
 
 
Fig. 8. The scheme of the pathogenesis of atherosclerosis. The inflammatory cascade 
in the artery is initiated by endothelial damage. Damaged endothelium expresses 
adhesion molecules (VCAM1) that interact with VLA4 on the surface of circulating 
monocytes and T cells. Damaged and dysfunctional endothelium permits the infiltration 
of immune cells as well as LDL into the arterial wall. Infiltrated monocytes differentiate 
into macrophages that recognise and engulf LDL that has been modified by reactive 
oxygen species (ROS). Lipid-loaded macrophages turn into foam cells that form the 
major component of the plaques. In addition, macrophages can present ApoB particles 
to CD4+ T cells that differentiate to Th1 cells and secrete pro-inflammatory mediators. 
oxLDL exposure also recruits smooth muscle cells (SMCs) from the media to the 
subendothelial space, where SMCs contribute to the plaque formation. As an adaptive 
response, macrophages and other cells secrete matrix metalloproteinases (MMPs) that 
digest extracellular matrix in the plaques. Although this process restrains the narrowing 
of the lumen, it also thins the fibrous cap and makes the plaque more vulnerable to 
rupture. Figure is modified from Hansson & Libby 2006. 
 
3 AIMS OF THE STUDY 
 
The current study was undertaken to investigate the effects of the trangenic 
melanocortin OE in Ldlr-deficient mouse model of atherosclerosis. By studying mice 
fed either regular CRM diet or Western-style diet, we aimed to evaluate the progression 
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of atherosclerosis in early and advanced phases of the disease, respectively. This study 
is a continuation of our previous studies indicating that 4-week melanocortin treatment 
has anti-inflammatory and vasoactive effects in pre-established atherosclerosis. The 
aims of the present study were: 
 
1) to study whether trangenic α- and γ3-MSH-OE ameliorates vascular function and 
mechanical properties of the aorta in atherosclerosis 
2) to evaluate whether transgenic α- and γ3-MSH-OE restrains the aortic 
inflammation in atherosclerosis 
3) to investigate whether transgenic α- and γ3-MSH-OE limits the plaque formation 
or alters the plaque characteristics 
 
4 MATERIALS AND METHODS 
 
4.1  Animals 
 
To study the long-term effects of the α- and γ3-MSH-OE in atherosclerosis, previously 
generated transgenic mouse model overexpressing α- and γ3-MSH was crossbred with 
Ldlr-/- mice (Savontaus, Breen et al. 2004). The transgene encodes N-terminal POMC, 
including α- and γ3-MSH and is under the control of the cytomegalovirus promoter that 
drives the expression of N-terminal POMC in all tissues. However, because prohormone 
convertases, which post-transcriptionally process N-terminal POMC to biologically 
active melanocortin peptides, are expressed only in certain cell types, α- and γ3-MSH-
OE is limited to these tissues (Benjannet, Rondeau et al. 1991). Thus, in this animal 
model, α- and γ3-MSH are processed correctly only in the tissues that normally process 
melanocortins, including the brain, skin, liver and heart (Savontaus, Breen et al. 2004). 
In these tissues α- and γ3-MSH concentrations are elevated two-fold compared to WT 
controls (Savontaus, Breen et al. 2004). 
 
Transgenic female (n=10) and male (n=17) MSH-OE-Ldlr-/- mice and their Ldlr-/- 
female (n=11) and male (n=20) controls were fed either with regular CRM diet or high-
fat, –cholesterol and –sugar Western diet (D12079B, Research Diets Inc.) to accelerate 
the disease development. Female mice were only fed with Western diet. Until the age of 
3 months, all mice were fed regular CRM diet. At the age of 3 months, 18 male and 21 
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female mice were placed on Western diet while CRM group of 19 male mice continued 
on the regular diet. The energy content of the Western diet was 4.7 kcal/g and it 
composed of 17 kcal% protein, 43 kcal% carbohydrate, and 41 kcal% fat where 0.21 
kcal% came from cholesterol. During the diet intervention, body weight and food 
consumption were monitored weekly. Thereafter, the tissues were weighted and 
collected for further analysis.  The duration of the diet was determined on the grounds 
of previous evidence showing that Ldlr-/- mice develop wide atherosclerotic lesions after 
4 months on high-fat diet (Silvola, Saraste et al. 2011). All experiments were carried out 
in homozygous MSH-OE Ldlr-deficient (MSH-OE) and in Ldlr-deficient (WT) mice. 
The study protocol is presented in Fig. 9. 
 
 
Fig. 9. The study protocol. At the age of 3 months, MSH-OE and WT mice were 
divided into CRM or Western groups. During 16-week diet-intervention, body weight 
and food consumption were monitored weekly after which the tissues were collected for 
further analysis. 
 
The experiments were planned to minimize the number of animals to be used. 
Euthanasia was carried out via CO2 asphyxiation. All animal experiments were 
approved by the Animal Experiment Board in Finland (license number ESAVI-
438/04.10.03/2012) and were performed according to European Union Directive 
2010/63/EU. 
 
4.2  Ex vivo vascular studies 
 
Rapidly after euthanasia, the thoracic aorta from the aortic arch to the diaphragm was 
placed in ice-cold oxygenated Krebs solution. Dissected 2 mm aortic ring was mounted 
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in a wire-myograph apparatus (Danish Myograph Technologies, Aarhus, Denmark) by 
threading it onto two wires (Ø=40 µm) and securing it to two supports. The wire-
myograph system allows controlling the circumference of the vessel while recording the 
force that the two wires place on the aortic ring. After mounting, vessel segment was 
allowed to equilibrate for at least 20 minutes before normalisation to 100 mmHg 
physiological tension. (Rinne, Nordlund et al. 2013)  
 
During the functional measurements, the distance between the two wires was kept 
constant. Isolated aorta was contracted three times with 62 mM KCl to determine the 
maximal contraction of the vessel. The vessel segments that were unresponsive to 
potassium were rejected from the results because unresponsiveness to potassium 
indicates that the vascular smooth muscle integrity is damaged. α1-adrenergic receptor-
mediated vasoconstrictor response was determined by cumulative doses of 
phenylephrine. Vessel was precontracted with 1 mM prostaglandin F2α to obtain 50-
80% of the maximal reference contraction to KCl for the monitoring and quantification 
of ACh-induced endothelium-dependent vasodilatation. Endothelium-independent 
relaxation was studied by adding cumulative concentrations of sodium nitroprusside 
(SNP), that acts as a vasodilator by releasing NO, to precontracted vessels. The 
contribution of NO to endothelium-dependent vasodilatation was determined by 
incubating the aortic ring with 100 µM L-NNA for 30 minutes before contracting the 
vessels with phenylephrine, and subsequently relaxing them with ACh. L-NNA is a 
competitive NOS inhibitor, and thus, prohibits the formation of NO. Vessel baths were 
washed at least three times with fresh, warm, and oxygenated Krebs solution between 
the different functional experiments. Krebs solution is a physiological salt solution 
composed of 119 mM NaCl, 25 mM NaHCO3, 5.5 mM glucose, 4.7 mM KCl, 1.2 mM 
KH2PO4, 1.2 mM MgSO4 ∙ 7H2O and 2.5 mM CaCl2 ∙ 2H2O. 
 
After functional experiments, aortic segment was equilibrated 30 minutes and 
subsequently studied for mechanical properties by a graded passive distension 
procedure. The two wires were brought together so that no tension was placed in the 
ring preparation and the micrometre was zeroed (L0). Then, the distance between the 
wires was increased stepwise by 20 µm every 60 seconds, until the micrometre reading 
reached 100 µm, and subsequently by 10 µm every 60 seconds until 30-40 mN wall 
force was reached. The wall force and micrometre reading were recorded at each step, 
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and the related wall stress (mN/mm) was calculated and plotted against the resulting 
strain (ΔL/L0). (Van Herck, De Meyer et al. 2009, Hadjinikolaou, Kotidis et al. 2004, 
Rinne, Ahola-Olli et al. 2015) 
 
During the functional and mechanical experiments, vessel segments were kept in 
oxygenated Krebs solution (95% O2 and 5% CO2) and heated to 37°C. Krebs solution in 
the myograph wells was discarded at least every 20 minutes and fresh, warm and 
oxygenated Krebs solution was provided to maintain the physiological properties of the 
vessels. Chart5 and PowerLab (ADI Instruments, Colorado Springs, CO) were used for 
the data recording and analysis. 
 
4.3 Plaque characterisation 
 
4.3.1 En face stainings 
 
The adventitia around the aortic arch was removed and the aortic arch was dissected. 
Aortic arch samples were fixed in 10% formalin for 24 hours and stored in phosphate-
buffered saline (PBS) at 4°C until staining. Any remaining adventitia from the aortic 
arch was removed before staining. The fixed aortic arch was dissected longitudinally 
open from the heart to the left subclavian artery and pinned flat intima upward.  
 
En face preparations of the aortic arch were stained with Sudan IV for atherosclerotic 
plaque quantification. 70% ethanol was added to the dish for 5 minutes. Filtered 0.5% 
(wt/vol) Sudan IV solution was applied for 6 minutes. Sudan IV (Sigma-Aldrich) was 
dissolved equally in acetone and 70% ethanol. Aortic arches were destained with 80% 
ethanol for 3 minutes and washed with PBS. The en face aortae were mounted on a 
glass plate under a coverslip using PBS. For quantitative analysis, images of the stained 
tissues were captured using Zeiss Stemi 2000-C stereomicroscope and Pixelink 
software. The intimal area was limited using image manipulation programme (GIMP 
2.8, GNU Image Manipulation Program). The atherosclerotic plaque area of the total 
intimal area was determined using automated image analysis software (ImageJ, Fiji, 
National Institutes of Health, Bethesda, Maryland, USA) with colour deconvolution 
plug-in (Ruifrok, Johnston 2001, Chen, Quan et al. 2010). 
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4.3.2 Immunohistochemical and histological stainings 
 
The aortic roots were embedded in Tissue-Tek O.C.T. (Sakura), frozen in isopentane on 
dry ice and stored at -70°C until further use. Transverse sections of aortic root (8 µm) 
were cut and stained with Oil Red O, Masson’s Trichrome, and Mac-3 and iNOS 
antibodies for the evaluation of lipid accumulation, collagen deposition, macrophage 
density and polarisation, respectively (Rinne, Silvola et al. 2014). For iNOS 
immunohistochemistry, the primary antibody concentration and fixation method were 
first optimised using three different primary antibody concentrations (1:50, 1:100 and 
1:200) and either methanol or acetone fixation and the results were evaluated under 
microscope. Finally, 1:100 primary antibody dilution and cold acetone were chosen for 
the staining. Aortic sections were fixed with cold acetone and staining was performed 
according to Abcam immunohistochemistry protocol in Scientific Shandon Sequenza 
Immunostaining Center (Thermo Fisher). Endogeneous peroxidase activity was 
suppressed with 1% H2O2 and the background staining was minimised by 1% bovine 
serum albumin (Sigma-Aldrich). Primary iNOS antibody (ab15323, Abcam) was 
applied and incubated for 18 hours in 4°C to ensure sufficient antibody binding. Using 
indirect immunohistochemistry method, the primary antibody was visualised by 
horseradish peroxidase-conjugated secondary antibody (ABC kit, Vector Laboratories) 
(Hsu, Raine et al. 1981). Finally, brown colour was developed with 3,3’-
diaminobenzidine tetrahydrochloride (D5637, Lot 60K0820, Sigma-Aldrich) and nuclei 
were counterstained with hematoxylin. The stained sections of the aortic roots were 
scanned using Pannoramic 250 digital slide scanner (3DHISTECH Ltd.) and the areas 
of intima and media were delimited using image editing software (GIMP 2.8, GNU 
Image Manipulation Program). To characterise the plaque features, the areas of intima 
and media were analysed by using an automated image analysis software (ImageJ, Fiji, 
National Institutes of Health, Bethesda, Maryland, USA) with colour deconvolution 
plug-in, which separates brown (macrophage), red (lipid) and blue (collagen) 
components (Ruifrok, Johnston 2001). 
 
4.4 Quantitative reverse-transcription polymerase chain reaction (RT-
qPCR) 
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The total RNA was isolated from the aorta by phenol/guanidine-based extraction 
(QIAzol Lysis Reagent, Qiagen). RNA quality and concentration were measured by 
spectrophotometer (BioSpec-nano, Shimadzu) and the RNA was reverse-transcribed to 
complementary DNA (Applied Biosystems) using 2729 Thermal Cycler (Applied 
Biosystems). RT-qPCR was carried out by 7300 Real Time PCR System (Applied 
Biosystems) and SYBR Green (KAPA Biosystems) was used to detect PCR products. 
Each sample was run in duplicate. Primer sequences for mouse genes are shown in 
Table 2. Target gene mRNA expression levels were normalised to the endogenous 
ribosomal S29 expression. The average ΔCt value of CRM WT samples served as a 
calibrator.  
 
Table 2. RT-qPCR primers for mouse genes.  
Gene name 
Accession number 






























4.5 Statistical analyses 
 
Statistical differences were calculated by 2-way analysis of variance (ANOVA) 
followed by Bonferroni post hoc tests, when multiple groups were compared or by 
unpaired two-tailed t test, when only two groups were compared. Concentration-
response curves in ex vivo wire-myograph were analysed by comparing maximal effect 
(Emax) and half maximal effective concentration (EC50) values using the extra sum-of-
squares F test. All statistical analyses were performed using GraphPad Prism 5.0 and 
6.0. P values of less than 0.05 were considered statistically significant. All data are 
presented as mean±standard error of the mean (SEM).   






5.1 Body and organ weights 
 
Apart from the regulation of cardiovascular and immune responses, the melanocortin 
system regulates several physiological functions, including energy homeostasis. Hence, 
we monitored the body weight development during diet-intervention and measured the 
weight of heart, liver and white adipose tissue (WAT) pads in the end of the study 
(Tables 2 and 3). 
 





    WT MSH-OE   WT MSH-OE 
 























Retroperitoneal WAT 0,349±0,050 0,255±0,040   0,481±0,055 0,501±0,051 
 
Table 3. Organ weights of female mice. Values are mean (g)±SEM. 
  
Western 
    WT MSH-OE 
 













Retroperitoneal WAT 0,239±0,041 0,203±0,018 
 
Body weight was monitored weekly during 16-week diet-intervention, while α- and γ3-
MSH-OE had no effect on the body weight development in either of the diet groups. In 
females, α- and γ3-MSH-OE tended to limit the body weight development; however, the 
difference was statistically nonsignificant (P=0.07) (Fig. 10).  
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Fig. 10. Body weight development in WT and MSH-OE mice on CRM and 
Western diet. α- and γ3-MSH-OE tended to decrease the Western-diet induced body 
weight development in female mice. Analysis was performed with 2-way ANOVA 
followed by Bonferroni post hoc tests. Data are mean±SEM, n=9-11 per group. 
 
Western diet significantly increased the epididymal and retroperitoneal WAT weights in 
males (P<0.0001 and P=0.0005, respectively). There were no differences between the 
epididymal/gonadal or retroperitoneal WAT weights between the genotypes at the end 
of the study; however, in females, α- and γ3-MSH-OE tended to decrease the gonadal 
WAT pad weight (P=0.06). (Fig. 11).  
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Fig. 11. WAT pad weights of WT and MSH-OE mice in the end of the study. A-B, 
Epididymal and gonadal WAT weights of male and female mice. C-D, Retroperitoneal 
WAT weights of male and female mice. In male mice, Western diet increased the 
epididymal and retroperitoneal WAT weights (### P<0.0001 for the diet effect). In 
females, α- and γ3-MSH-OE tended to decrease the gonadal WAT weight. Analysis was 
performed with 2-way ANOVA followed by Bonferroni post hoc tests (males) or with 
unpaired two-tailed t test (females). Data are mean±SEM, n=8-11 per group. 
 
At the end of the study, α- and γ3-MSH-OE had no effect on body weight in either 
males or females. However, Western diet significantly increased the body weight in 
males (P=0.006, Fig. 12A-B). Similarly, Western diet increased the relative liver weight 
in males (P<0.0001). α- and γ3-MSH-OE significantly decreased the relative weight of 
liver in males (P=0.03), while female MSH-OE mice had increased liver weights in the 
end of the study (P=0.047, Fig. 12C-D). Genotype had no effect on heart to body weight 
ratio in male or female mice. The diet, however, decreased the heart/body weight ratio 




























































































Fig. 12. Body weight and relative weights of liver and heart in the end of the study. 
A-B, Western diet increased the body weight in male mice (## P<0.005 for the diet 
effect). C-D, Male mice on Western diet showed increased liver weight in relation to 
body weight (### P<0.0001 for the diet effect). On Western diet, male MSH-OE mice 
had smaller livers than their WT controls (* P<0.05 for the genotype effect). Female 
mice had increased liver weights. E-F, Heart/body weight ratio was smaller in male 
mice on Western than on regular CRM diet. Analysis was performed with 2-way 
ANOVA followed by Bonferroni post hoc tests (males) or with unpaired two-tailed t 
test (females). Data are mean±SEM, n=8-11 per group. 
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5.2 Ex vivo vascular studies 
 
To test the hypothesis that α- and γ3-MSH-OE alleviates vascular dysfunction in 
atherosclerosis, the functional and mechanical properties of the isolated aortae were 
examined by wire-myograph.  
 
The isolated aortae were stimulated three times with 62 mM potassium solution. The 
maximal potassium-evoked constriction was observed on the third, or sometimes on the 
second, potassium stimulation. In the Western group, the maximal potassium-evoked 
contractions were weaker than those of regular CRM diet group (P=0.04 for the diet 
effect, Fig. 13A). 
 
Contractile-responses were also studied using cumulative doses of phenylephrine. The 
contraction response in the aortae of WT mice compared to the aortae of MSH-OE mice 
on regular diet was increased (P<0.01, Fig. 13B). Thus, α- and γ3-MSH-OE restrained 
the contractile effect of phenylephrine. The α- and γ3-MSH-OE resisted the contractile 
responses only in mice placed on CRM, but not on Western, diet (P=0.0015, Fig. 13B-
C).  
 
Fig. 13. Contraction responses to potassium and phenylephrine in the isolated 
aortae of WT and transgenic MSH-OE mice. A, Maximal contraction evoked by 62 
mM K+. On Western diet, the maximal potassium-evoked contractions were weaker 
than on CRM diet (# P<0.05 for the diet effect). B-C, Concentration–response curves 
for phenylephrine (PE)–induced contractions with regular CRM and Western diet. WT 
mice had increased contraction responses compared to MSH-OE mice on CRM diet (** 
P<0.01 for the genotype effect). Analysis was performed by 2-way ANOVA followed 
by Bonferroni post hoc tests and extra sum-of-squares F test. Data are mean±SEM, n=6-








































































































After evaluating contractile responses, endothelium-dependent vasorelaxation responses 
of the aortae were studied. The α- and γ3-MSH-OE significantly improved the 
vasorelaxation responses in mice on regular diet (P<0.0001 for logEC50). There was no 
improvement in mice placed on Western diet (Fig. 14B). The contribution of NO to this 
ACh-evoked vasodilatation was studied by adding NOS inhibitor L-NNA to the organ 
well. Subsequently, the cumulative concentration series of ACh were performed. Now, 
when the aortae were pretreated with L-NNA and contracted again, the relaxation 
responses were markedly blunted (Fig. 14C-D).  
 
To evaluate the endothelium-independent vasodilatation responses, NO donor SNP was 
added to the organ bath. SNP induced a profound relaxation of the aortae in both 
genotypes (Fig. 14E-F). However, the endothelium-independent responses were similar 
between the genotypes, suggesting that the genotype effect on vasodilatory responses is 
limited to endothelium-dependent mechanisms.  




Fig. 14. Vasorelaxation responses of the aortae in WT and MSH-OE mice on 
regular CRM or Western diet. A-D, Endothelium-dependent relaxations to ACh 
before and after the addition of L-NNA. E-F, Endothelium-independent relaxation 
response to SNP. α- and γ3-MSH-OE improved the endothelium-dependent 
vasorelaxation responses on CRM diet (**** P<0.0001 for genotype effect). The 
statistical analyses were performed using extra sum-of-squares F test. Data are 
mean±SEM, n=5-12 per group in each graph.  
 
To characterise the distensibility of the arteries, the isolated aortae were placed on 
mechanical strain and wall stress-strain curves were obtained. There were no 
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statistically significant differences in the stress-strain curves between the groups (Fig. 
15).  
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Fig. 15. The stress-strain curves of the aortae of WT and MSH-OE male mice on 
CRM and Western diets. There was no statistically significant difference in arterial 
stiffness between MSH-OE and WT mice on regular or Western diet. The statistical 
analyses were performed using extra sum-of-squares F test. Values are mean±SEM, 
n=10-14 per group. 
 
5.3 Plaque characterisation 
 
The atherosclerotic plaques in the aortic arch and aortic root were characterised by en 
face tissue, immunohistochemical and histological stainings. 
 
5.3.1 En face stainings of the aortic arch 
 
To determine intimal plaque deposition in the aortic arch, en face aortic arches were 
stained with Sudan IV. In male mice, the diet significantly increased the plaque 
accumulation in the intima (P<0.0001 for the diet effect). On the Western diet, MSH-
OE mice displayed significantly less intimal plaque accumulation in both males and 
females compared to WT mice (P=0.03 and P=0.02, for genotype effect, respectively) 
(Fig. 16). 
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Fig. 16. Plaque area in the aortic arch represented as Sudan IV -stained intimal 
area. A-D, Representative Sudan IV -stained en face preparations of the aortic arch of 
WT and MSH-OE mice on CRM or Western diet. E, The intimal plaque area was 
smaller in MSH-OE male mice compared to WT mice on Western diet (* P<0.05 for the 
genotype effect). In males, Western diet significantly increased the plaque development 
(#### P<0.0001 for the diet effect). F, In females, α- and γ3-MSH-OE decreased the 
plaque development in the aortic arch. Statistical differences were analysed by 2-way 
ANOVA followed by Bonferroni post hoc tests (males) or unpaired t test (females). 
Values are mean±SEM, n=9-10 per group.  
 
5.3.2 Histological stainings 
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5.3.2.1 Oil Red O 
 
The absolute lesion area was calculated from Oil Red O stained aortic roots to evaluate 
the plaque size. Although the genotype had no effect on the plaque formation, the diet 
significantly increased the plaque size (P<0.0001) (Fig. 17). 
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Fig. 17. The absolute lesion area (mm2) represented as accumulated lipids in the 
intima in WT and MSH-OE mice on regular CRM or Western diet. A-D, 
Representative Oil Red O stained sections of aortic root of WT and MSH-OE mice on 
CRM or Western diet. The diet significantly increased the absolute lesion area (#### 
P<0.0001 for diet effect). Analysis was performed with 2-way ANOVA followed by 
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5.3.2.2 Masson’s Trichrome 
 
Masson’s Trichrome stained aortic sections were analysed for the evaluation of collagen 
deposition. Collagen deposition did not differ statistically between the genotypes in 
males on Western diet (Fig. 18). 
Fig. 18. The absolute (mm2) and proportional collagen area represented as 
Masson’s Trichrome stained intimal area in WT and MSH-OE mice on Western 
diet. A-B, Representative Masson’s Trichrome stained sections of aortic root of WT and 
MSH-OE mice on Western diet. C-D, The collagen depositions between the genotypes 
did not differ statistically significantly. Analyses were performed using unpaired t test. 
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Immunohistochemical Mac-3 stainings of the aortic root were analysed to quantify the 
macrophage density in the aortic root. There was no significant genotype effect on the 
proportion of macrophages (Fig. 18B) or the absolute macrophage count in the intima in 
males on Western diet (Fig. 18C).                           
        
Fig. 18. The absolute (mm2) and proportional Mac-3-positive area of the intima in 
WT and MSH-OE mice on Western diet. A-B, Representative Mac-3-stained sections 
of aortic root of WT and MSH-OE mice on Western diet. C-D, The macrophage density 
and the absolute macrophage count means did not differ statistically significantly 
between two genotypes. Analysis was performed using unpaired t test. Values are 
mean±SEM, n=7-9 per group. 
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Immunohistochemical iNOS stainings of the aortic root were performed for the 
characterisation of the macrophage phenotype. The proportion of iNOS-positive area in 
the intima was smaller in MSH-OE mice, indicating a decreased M1 macrophage 
deposition (Fig. 18). 
 
 
Fig. 18. The absolute (mm2) and proportional iNOS-positive area in the intima in 
WT and MSH-OE mice on Western diet. A-B, Representative iNOS-stained sections 
of aortic root of WT and MSH-OE mice on Western diet. D, The proportion of iNOS-
stained intimal area was smaller in MSH-OE mice compared with WT mice (* P<0.05 
for genotype effect). Analysis was performed using unpaired t test. Values are 




Total RNA from the thoracic aortae of WT and MSH-OE mice was extracted and used 




















































The mean expression levels of Il6, Ccl2 and Ccl5 were statistically significantly lower 
in MSH-OE mice vs. WT mice on Western diet (P=0.04, P=0.003 and P<0.0001, 
respectively) (Fig. 19B-D). There was no genotype effect of these cytokines on regular 
diet. The Western diet significantly increased the expression level of Ccl2 and Ccl5 
(P=0.003 and P<0.0001 for diet effect, respectively); however, the diet effect on Il6 
expression did not quite reach the statistical significance (P=0.07 for the diet effect). α- 
and γ3-MSH-OE, thus, seemed to alleviate the diet-induced increase in Ccl2 and Ccl5 
expression. There was no difference in inos or enos expressions between the genotypes. 









Fig. 19. Relative mRNA expressions of inflammatory markers in the thoracic aorta 
of WT and MSH-OE mice on regular CRM and Western diet. Western diet 
increased the expressions of Ccl2, Ccl5 and inos (## P<0.001, #### P<0.00001 for the 
diet effect). On Western diet, α- and γ3-MSH-OE decreased the expressions of Il6, Ccl2 
and Ccl5 (* P<0.05, ** P<0.001, **** P<0.00001 for the genotype effect). Statistical 
differences were calculated using 2-way ANOVA followed by Bonferroni post hoc 







































































































































































































6.1 Methodological considerations 
 
6.1.1 Animal model 
 
The present study was conducted to determine the effects of the trangenic melanocortin 
OE in atherosclerosis. Transgenic mice overexpressing α- and γ3-MSH and deficient in 
Ldlr were used as an experimental model. Ldlr deficiency in mice is analogous to 
human familial hypercholesterolemia that is caused by either heterozygous or 
homozygous LDLR deficiency. The prevalence of the homozygous form is very rare, 
affecting only about 1 in 160 000 to one million people worldwide, whereas 
heterozygous mutation in LDLR is 1 in 200 or 500 worldwide, so it is relatively 
common (The FH Foundation 2015). Although the homozygous Ldlr-/- model is not 
perfectly comparable to human situation, it provides a useful tool for studying 
atherosclerosis in mice because normally they have low cholesterol levels and a 
protective lipoprotein profile, and therefore, do not normally develop atherosclerosis 
(Mills, Taylaur 1971). Furthermore, atherogenic diet consisting of high fat and 
cholesterol promotes the disease development so that Ldlr-/- mice develop major lesions 
already after 4 months on the diet. This, of course, accelerates the research when life-
long animal studies are impractical to conduct. However, the situation is relatively 
different in humans where the development of atherosclerosis can take decades. In 
addition, Ldlr-/- mice rarely demonstrate plaque ruptures, which are the most serious 
clinical events in humans.  
 
Despite its limitations, this transgenic mouse provides major advantages over 
conventional pharmacological models, including stable MSH levels without frequent 
and tightly scheduled peptide injections. Because there is no need to inject the peptides 
and adjust the dose for each animal, the possibility of human mistakes, which again 
might alter the peptide levels, is lower. Moreover, the injections cause additional stress 
to the animals. In addition, transgenic approach provides a life-long α- and γ3-MSH-OE 
“administration” that would not be feasible to conduct using conventional MSH peptide 
administration. However, because the transgene comprises both α- and γ3-MSH, a 
limitation of this model is that it is not possible to distinguish the contributions of α- and 
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γ3-MSH and the respective receptors to the observed anti-inflammatory and vasoactive 
effects. Given that both α- and γ3-MSH display these effects, it is likely that they both 
contribute to the observed phenotype. The receptors for α- and γ3-MSH, namely MC1R 
and MC3R, are widely distributed in the periphery and in the CNS, and as such, the 
therapeutic effects of α- and γ3-MSH-OE are likely to be mediated via both peripheral 
and central mechanisms. Recently, it was shown that deficiency of either MC1R or 
MC3R disturbs the anti-inflammatory signalling (Holloway, Durrenberger et al. 2015, 
Rinne, Ahola-Olli et al. 2015). However, it seems that MC3R plays a more significant 
role in the acute inflammatory response, whereas MC1R contributes more to the 
delayed immune response (Holloway, Durrenberger et al. 2015). Because both MC1R 
and MC3R have shown advantageous effects in inflammation and cardiovascular 
regulation, from a drug development point of view, it might be more beneficial to 




The method of studying contractile and mechanical properties of the arteries, wire-
myograph, was first described in 1977 by Mulvany and Halpern and has since been used 
to study various ring preparations (Mulvany, Halpern 1977). In the current study, wire-
myograph was used to evaluate the functional and mechanical changes in the 
atherosclerotic aorta. The reason of studying aortae instead of any other vessel segment 
was that atherosclerosis is a disease that manifests in the large and medium-sized 
arteries. In addition, the aorta is the largest artery is mice, which simplifies the 
mounting procedure. 
 
The standard procedure of preparing the arteries for the myograph apparatus aims at 
keeping the vessels functional for the experiments. Although the mounting procedure is 
performed carefully, it causes stress upon the aortae, which can affect their function. 
 
Wire-myography is an ex vivo analysis method, and thus, has a great analytical power 
(Angus, Wright 2000). In a wire-myograph system, ring preparations can be studied for 
over 12 hours, which is impossible in vivo. In the absence of circulating hormones and 
neuronal innervations, every aortic ring can be studied without the interference of 
homeostatic mechanisms (Angus, Wright 2000). This enables the evaluation of the 
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underlying pathological mechanisms more accurately than in vivo. However, without 
the surrounding tissue and circulating hormones, the results obtained from the isolated 
arteries should be carefully considered before extrapolating them to in vivo situation.  
 
6.2 Metabolic changes in MSH-OE mice 
 
In this thesis, we carefully monitored the body weight development and body 
composition during the study. In males, α- and γ3-MSH-OE had no effect on body 
weight development during the diet-intervention, whereas in females, α- and γ3-MSH-
OE tended to limit the Western diet induced body weight gain. This tendency in weight 
loss might result from decreased gonadal WAT mass that was almost statistically 
significantly decreased in MSH-OE mice compared with WT. α-MSH is an anorexic 
peptide, so it decreases the appetite and increases the energy expenditure. Similarly, [D-
Trp8]-γ-MSH has been shown to decrease food intake, although versatile results exist 
(Marks, Hruby et al. 2006, Lee, Kim et al. 2008). Because there were no differences in 
body weights between MSH-OE and WT mice, it can be concluded that the beneficial 
vasoactive and anti-inflammatory effects were not due to the weight loss effect of α- 
and γ3-MSH. Considering that obesity is a major risk factor for cardiovascular diseases, 
weight-reducing therapy would be beneficial especially for those patients at risk for 
cardiovascular event. 
 
Furthermore, α- and γ3-MSH-OE decreased the relative liver weight in male mice on 
Western diet, opposite to female mice, whose relative liver weights were increased. 
These results most probably stem from accumulated fat deposits in the liver caused by 
Western diet. The accumulation of fat deposits in the liver impairs the normal function 
of the liver, including fat and glucose metabolism. This state called steatohepatitis is a 
major risk factor for atherosclerosis. In MSH-OE males, it could be speculated if 
decreased relative liver weight was due to decreased fat accumulation caused by α- and 
γ3-MSH-OE. However, the absolute liver weights were unchanged. The differences in 
relative liver weights between males and females might stem from differencent 
suscetibilities in the hepatic lipid accumulations.  
 
6.3 Vascular properties in MSH-OE mice 
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One of the objectives of this thesis was to study whether transgenic α- and γ3-MSH-OE 
ameliorates vascular function and mechanical properties of the aortae in atherosclerosis. 
During the development of atherosclerosis, endothelial damage and dysfunction are 
observed in the vasculature even before the plaque formation. The damaged 
endothelium changes the tone of the vasculature so that vasoconstriction predominates. 
(Davignon, Ganz 2004) This pathological change was also observed in this project. α- 
and γ3-MSH-OE had no effect on the potassium-evoked vasoconstriction, but it resisted 
the phenylephrine-induced contractions, and thus, improved the function of the aorta. α- 
and γ3-MSH-OE also enhanced the endothelium-dependent vasorelaxation when mice 
were fed regular CRM diet. Most probably these effects were absent in Western group 
because the diet causes major endothelial dysfunction that overrules the beneficial 
effects of α- and γ3-MSH-OE. Because eNOS is mainly responsible for the NO 
synthesis in the vascular endothelium, we hypothesized that enos would be upregulated 
in the aortae of MSH-OE mice. Since its expression was unchanged, the enhanced 
endothelium-dependent vasodilation most likely originated from other mechanisms than 
increased transcription. Previously, Rinne et al. showed that α-MSH stimulates 
phosphorylation of eNOS at Ser1177 residue and decreases oxidative stress-mediated 
NO breakdown, which together augment NO availability (Rinne, Nordlund et al. 2013, 
Rinne, Ahola-Olli et al. 2015). The present and previous evidence demonstrate that α- 
and γ3-MSH-OE ameliorates endothelial dysfunction by promoting endothelium-
dependent vasodilation without directly modifying enos expression. In the present 
study, α- and γ3-MSH-OE had no effect on the aortic distensibility, although we had 
showed previously that Mc1r-deficiency stiffens the aorta (Rinne, Ahola-Olli et al. 
2015). 
 
6.4 Plaque characteristics in MSH-OE mice 
 
This thesis showed that α- and γ3-MSH-OE significantly decreased the plaque 
accumulation in the aortic arch. On the contrary to our previous study, where we treated 
the atherosclerotic mice for 4 weeks with MT-II, there was no difference in the plaque 
size (Rinne, Silvola et al. 2014). However, this difference in results most probably 
stems from the animal models used, i.e. melanocortin administration versus transgenic 
MSH-OE. Although MT-II is a very potent α-MSH analogue and the treatment duration 
of 4 weeks was able to constrain the development of atherosclerosis, this duration might 
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be insufficient to limit the plaque accumulation, when the mice had already developed 
atherosclerosis before the treatment initiation. In the present study, on the other hand, 
the transgenic α- and γ3-MSH-OE provided a life-long MSH “treatment”, and therefore, 
might be more efficient in limiting and even preventing the plaque accumulation at the 
early stage of the disease development. Moreover, the transgenic model provides 
consistent and stable activation of the melanocortin system, whereas the administration 
of MSH peptides requires frequent i.p. injections and therefore the level of MSH 
peptides might vary significantly throughout the day, which again might decrease the 
therapeutic effects.  
 
Apart from plaque size, the clinical outcome in atherosclerosis is determined by the 
composition of the plaque. As the disease progresses, MMPs degrade the fibrotic tissue 
as an adaptive response to decreased lumen area, which thins the collagen cap and 
makes it susceptible to rupture. As a marker for plaque instability, we determined the 
collagen deposition and found that α- and γ3-MSH-OE did not decrease the collagen 
deposition, i.e. α- and γ3-MSH-OE had no effect on plaque instability. Given that α-
MSH and Mc1r-deficiency have been shown to modulate collagen synthesis (Böhm, 
Stegemann 2014, Lorenz, Seebach et al. 2014, Rinne, Ahola-Olli et al. 2015), the 
differences in our results might yield from insufficient sample quality. Moreover, the 
plaque accumulation decreases when receding from the aortic root, and therefore, the 
differences in section points in relation to aortic valves might distort the results. In this 
project, Masson’s Trichrome staining were performed only for Western group, which is 
why it is possible that pathological mechanisms in atherosclerosis override the 
beneficial effects of α- and γ3-MSH-OE as mentioned above. 
 
6.5 Anti-inflammatory properties in MSH-OE mice 
 
The decreased plaque accumulation in MSH-OE mice is well in line with the reduced 
cytokine expression levels observed in this study. Ccl2 deficiency or polymorphism 
decreases the plaque burden both in mice and humans (Wan, Murphy 2013). The 
atherogenic effects of CCL2 stem from its ability to recruit monocytes into the 
inflammatory site; the effect that is abolished in Ccr2-deficient mice (Boring, Gosling et 
al. 1997, Boring, Gosling et al. 1998). Similarly, Ccr5-deficient bone transplantation in 
mice decreases the plaque burden and monocyte trafficking to the site of inflammation 
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(Potteaux, Combadiere et al. 2006, Braunersreuther, Zernecke et al. 2007). In addition 
to Ccl2 and Ccl5, Il6 was also decreased in the aorta of MSH-OE mouse. In another 
atherosclerotic mouse model, in Apoe-/- mouse, Il6 expression is also significantly 
increased (Sukovich, Kauser et al. 1998); the effect that we also observed in our Ldlr-/- 
mouse. IL6 is secreted by macrophages in the atherosclerotic plaques; and especially, 
macrophages loaded with free cholesterol are a major source of IL6 (Sukovich, Kauser 
et al. 1998). Although IL6 has been considered as an atherogenic molecule, some 
studies indicate that IL6 would be atheroprotective (Van Lenten, Wagner et al. 2001, 
Schieffer, Selle et al. 2004). 
 
Our findings show that α- and γ3-MSH-OE was able to decrease the proportion of a M1 
macrophage marker iNOS in the aortic root. M1 macrophages feed plaque inflammation 
and promote vulnerability by secreting pro-inflammatory markers, such as iNOS. In the 
present study we show that α- and γ3-MSH-OE decreased the iNOS-positive area in the 
aortic root. This might be an indication of the ability of α- and γ3-MSH-OE to shift the 
macrophage phenotype towards anti-inflammatory M2 type (Rinne, Silvola et al. 2014).  
Still, more research is needed to confirm the switch of macrophage phenotype by α- and 
γ3-MSH-OE. M1 macrophages secrete proinflammatory cytokines, including IL1 and 
IL6. Supporting the iNOS findings, Il6 expression was significantly suppressed in 
MSH-OE mice, possibly due to reduced M1 macrophage deposition. Moreover, other 
pro-inflammatory markers Ccl2 and Ccl5 that recruit leukocytes were downregulated in 
MSH-OE mice (Wan, Murphy 2013). Recently, Yang et al. showed that α-MSH was 
able to reduce the infiltration of monocytes by downregulating the expression of 
VCAM-1 that also promotes the arrest of monocytes and T cells in the endothelium 
(Cybulsky, Iiyama et al. 2001, Yang, Zhang et al. 2015). Given that the endothelium 
and endothelium-derived NO play a crucial role in controlling the leukocyte adhesion 
and cytokine secretion, it might be that the anti-inflammatory actions of melanocortins 
are governed by enhanced NO bioavailability (Rinne, Silvola et al. 2014). Morover, NO 
protects the vasculature by restraining smooth muscle cell proliferation, LDL oxidation 
and inflammatory responses, which are all compromised in atherosclerosis (Davignon, 
Ganz 2004).  
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6.6 Future perspectives 
 
In this thesis, the long-term activation of the melanocortin system in a transgenic mouse 
model showed therapeutical potential in protecting against atherosclerosis. As an 
endogeneous peptide system, the melanocortin system regulates a wide range of 
homeostatic functions, including immune and cardiovascular system. Due to these 
characteristics, the melanocortin system appears as an ideal drug development target for 
atherosclerosis, an inflammatory disease of the arteries. However, owing to such wide 
range of functions, activation or deactivation of this system is unlimited to certain 
tissues or cells. Furthermore, MCRs are widely distributed in the body, including the 
CNS, and hence targeting these receptors might yield in unwanted effects on, for 
example, sexual functions or energy homeostasis. The discovery and development of 
melanocortin ligands that would be specific to the tissue- or receptor-of-interest might 
reduce the side effects and induce the beneficial effects. Still, these results should be 
carefully examined before further extrapolation to humans and more research should be 
conducted to evaluate the definitive therapeutic potential of the melanocortinergic 




This study using a transgenic MSH-OE mouse model demonstrates that α- and γ3-MSH-
OE is able to alleviate the progression of atherosclerosis in mice. The main conclusions 
of this thesis are: 
 
1. Trangenic α- and γ3-MSH-OE limits the plaque accumulation in the aortic arch 
when the mice are challenged with Western-style diet. 
2. Transgenic α- and γ3-MSH-OE alleviates the endothelial dysfunction in 
atherosclerosis by shifting the vascular tone towards vasodilatation instead of 
vasoconstriction that is often observed in atherosclerosis. 
3. Trangenic α- and γ3-MSH-OE limits the diet-induced elevation of the pro-
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